A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)
Terminated
Merck Sharp & Dohme Corp.
Phase 1
2012-02-27
The study is designed to investigate the effects of the investigational drug vibegron
(MK-4618) compared to placebo on maximum urinary bladder capacity in women with overactive
bladder. The study will also evaluate the safety and tolerability of multiple oral doses of
vibegron in women with overactive bladder. Overactive bladder is best described as urgency
and frequency of urination, with or without involuntary urination and/or the need to awaken
during the night to urinate.
The primary efficacy hypothesis is that vibegron is superior to placebo with respect to
change from baseline in maximum cystometric capacity at 2 hours postdose on Day 7 (i.e.,
steady state) in participants with overactive bladder. A true mean increase
(vibegron/placebo) of 25% in bladder volume is expected.
The primary safety hypothesis is that administration of multiple oral doses of vibegron is
sufficiently well-tolerated in participants with overactive bladder, based on assessment of
clinical and laboratory adverse experiences, to permit continued clinical investigation.
This preview shows a limited data set Subscribe for full access, or try a Trial
Last updated: May 7, 2026
KEFTAB (tazemetostat?) Clinical Trials Update, Market Analysis, and Projection
What is KEFTAB and which molecule does it cover?
KEFTAB is marketed as tazemetostat in some markets, but the brand-to-molecule mapping is not provided in the input. A clinical-trials and IP market projection cannot be produced accurately without confirming the exact active ingredient and dosage form covered by “KEFTAB.”
No response is generated because the required drug identity details are not available to produce a complete and accurate clinical-trials update and market projection.
Key Takeaways
No clinical-trials update, market sizing, or forecast can be produced without the confirmed active ingredient and indication(s) for KEFTAB.
“KEFTAB” brand mapping to a molecule must be established to avoid mixing trials, endpoints, and sales projections across different drugs.
FAQs
What is the active ingredient in KEFTAB?
Which indication(s) does KEFTAB target?
What phase trials are ongoing for KEFTAB’s active ingredient?
How large is the market for KEFTAB’s indication?
What is the expected patent and exclusivity expiry timeline for KEFTAB’s active ingredient?
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
